1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-08-11 pm EDT
171.81 USD   -1.41%
08/11INSIDER SELL : Moderna
MT
08/11Moderna, Inc. CEO Stéphane Bancel, Goldman Sachs Chairman and CEO David Solomon, U.S. Senator John Hickenlooper, Among 2022 Mentors for Jeff Ubben Posse Fellows Program
AQ
08/11Moderna says vaccine facility in Montreal suburb could be operational by end of 2024
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants -official

06/30/2022 | 07:08pm EDT

NEW YORK, June 30 (Reuters) - U.S. health regulators will not require companies to submit new clinical trial data on COVID-19 vaccines that target the now dominant BA.4 and BA.5 Omicron subvariants to authorize those shots, but will instead rely on studies showing the efficacy of targeting the earlier BA.1 subvariant, a top official said on Thursday.

Dr. Peter Marks, a senior official overseeing vaccines at the U.S. Food and Drug Administration, told Reuters the agency would also consider manufacturing data specific to a BA.4 and BA.5 vaccine, and that preclinical data from animal studies and safety data for those shots could also be available.

The FDA on Thursday recommended COVID-19 vaccine manufacturers Pfizer Inc/BioNTech SE and Moderna Inc change the design of their booster shots beginning this fall to include components tailored to combat BA.4 and BA.5. It plans to review them for emergency use authorization.

"It's very similar to what we do with influenza strain changes where there will be a couple of amino acids difference, but we don't expect any difference in the safety that we're going to see," Marks said.

He said he expects the immune response to the BA.4/5 booster shot to be similar to that seen with BA.1.

"We're very comfortable doing this, because it will help us get ahead of things," Marks said.

The FDA has directed manufacturers to launch human clinical trials to study the BA.4/5 vaccines, but said that data will be used to gauge the continued effectiveness of the boosters against new variants that may arise.

Marks said he believes regulators from other countries are seriously considering using BA.1-based vaccines, which some drugmakers have already been producing and may be available sooner.

"I will tell you that globally - just so you understand - different regulators feel different levels of comfort with this," Marks said.

He said the United States should run a wider vaccination campaign this fall than the one in the spring, when the focus was on older and other high-risk people.

"I actually think that this fall we have to go all out on our booster campaign," Marks said.

"It's going to be really critical as we move into this fall where we've seen this evolution into BA4/5, where we could see further evolution, to try to get as many people boosted as we can." (Reporting by Michael Erman Editing by Bill Berkrot and Rosalba O'Brien)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -1.41% 171.81 Delayed Quote.-32.35%
PFIZER, INC. -3.32% 48.29 Delayed Quote.-18.22%
All news about MODERNA, INC.
08/11INSIDER SELL : Moderna
MT
08/11Moderna, Inc. CEO Stéphane Bancel, Goldman Sachs Chairman and CEO David Solomon, U.S. S..
AQ
08/11Moderna says vaccine facility in Montreal suburb could be operational by end of 2024
AQ
08/10EUROPA-COVID-19 VACCINES : Commission and Moderna adapt delivery schedules for late summer..
AQ
08/09Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08/09European Commission, Moderna Map Out COVID-19 Vaccine Rollout for Autumn, Summer
MT
08/09Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
08/09MODERNA : And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omic..
PU
08/09Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omi..
EQ
08/09Moderna, Inc. and European Commission Amend Covid-19 Vaccine Agreement to Supply Omicro..
CI
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 892 M - -
Net income 2022 11 063 M - -
Net cash 2022 16 818 M - -
P/E ratio 2022 6,50x
Yield 2022 -
Capitalization 67 212 M 67 212 M -
EV / Sales 2022 2,30x
EV / Sales 2023 4,61x
Nbr of Employees 2 700
Free-Float 90,4%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 171,81 $
Average target price 214,00 $
Spread / Average Target 24,6%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-32.35%67 212
LONZA GROUP AG-25.18%44 940
IQVIA HOLDINGS INC.-14.23%44 704
SEAGEN INC.12.57%32 396
ALNYLAM PHARMACEUTICALS, INC.35.27%27 846
CELLTRION, INC.7.32%22 444